Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas
NCT04295759Phase 1Completed
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aderbasib in glioma, sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Number of Patients Who Experienced Dose-limiting Toxicities at 28 days, Maximum Tolerated Dose and/or Recommend Phase II Dose at 28 days and 4 more. Started Jul 2020; status: completed.
02
Drugs
aderbasib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04295759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295759.